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Buruli Ulcer, 
Central African 
Republic 
To the Editor: Buruli ulcer, the 
third most common mycobacterial 
disease of humans after tuberculosis 
and leprosy, is an important disﬁ  gur-
ing and disabling cutaneous infection 
disease caused by Mycobacterium ul-
cerans. Buruli ulcer was declared an 
emerging skin disease of public health 
concern by the World Health Orga-
nization (WHO) in 1998. Although 
the disease is known to be associated 
with swampy areas and environmental 
changes, the mode of transmission is 
not yet clearly understood. A possible 
role for water bugs in the transmission 
has been postulated in the last 10 years. 
In this direction, several researchers 
have proposed that biting water bugs 
could be vectors for M. ulcerans (1). 
M. ulcerans produces a potent toxin 
known as mycolactone (2), which ly-
ses dermal cells, leading to the devel-
opment of continuously expanding ul-
cers with undermined edges. Surgery 
is the only treatment for late lesions, 
which involves excision of necrotic 
tissues, followed by skin grafting. Af-
ter such treatment, patients suffer from 
functional limitations, social stigmati-
zation, and the loss of livelihood (3). 
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Figure. Dendrogram for NotI-digested pulsed-ﬁ   eld gel electrophoresis proﬁ  les  of  Vibrio 
cholerae isolates, Laos, December 2007–January 2008. Origin of each isolate is shown 
on the right. *Water sample.LETTERS
Antimicrobial drug treatment is avail-
able (a combination of rifampin and 
streptomycin), but it is effective only 
for early lesions (4).
The disease is endemic in rural 
wetlands of tropical countries of Af-
rica, the Americas, and Asia. Over the 
past decade, the prevalence of Buruli 
ulcer was highest in western Africa 
(3,5), with an alarming increase in 
detected cases. In central Africa, foci 
of Buruli ulcer have been reported in 
Gabon, Equatorial Guinea, Cameroon, 
Congo, the Democratic Republic of 
Congo, and Sudan (6), which are all 
neighboring countries of the Central 
African Republic (CAR). Surprisingly, 
in CAR, no cases of Buruli ulcer have 
been reported so far, even though its 
presence in this country was suspected 
in 2006, although not conﬁ  rmed. This 
situation motivated us to begin a pas-
sive survey in the hospitals of Bangui, 
the capital of CAR. We report here 2 
conﬁ  rmed cases of Buruli ulcer that 
were found through this survey. The 2 
patients were admitted in April 2007 
to Hôpital de l’Amitié, Bangui, CAR, 
with extensive skin ulcers, which 
might correspond to Buruli ulcer ac-
cording to WHO guidelines (7). Both 
patients were farmers from the Om-
bella M’poko region. They lived on 
the border of the M’poko River and 
carried out daily activities in an aquat-
ic environment.
The ﬁ  rst patient was a 62-year-old 
man who had a large ulceration of the 
right limb (Figure, panel A). Differen-
tial diagnosis eliminated other ulcer-
ative diseases such as drepanocytosis, 
and the patient was HIV negative. For 
bacteriologic diagnosis, 4 samples 
were taken with sterile cotton swabs 
from beneath the undermined edges of 
the ulcer. Proteus mirabilis was isolat-
ed from the lesion, and a few acid-fast 
bacilli were shown by Ziehl-Neelsen 
(ZN) staining. Unfortunately, 1 week 
later, the patient died of an unknown 
cause.
The second patient was a man of 
the same age who had an ulceration 
6.5 cm in diameter on the left ankle 
(Figure, panel B). His condition had 
been treated with various antimicro-
bial agents without any result. Blood 
testing showed minor anemia (hemo-
globin 12.4 g/dL) and that the patient 
was HIV negative. Bacteriologic 
analysis found no gram-positive and 
gram-negative bacteria, and ZN stain-
ing showed the presence of acid-fast 
bacilli. He received the speciﬁ  c rec-
ommended treatment for M. ulcerans 
infection (antimicrobial drug regimen: 
rifampin, 10 mg/kg, and streptomycin, 
15 mg/kg), and the lesions had receded 
2 months later (Figure, panel C).
The identiﬁ  cation of M. ulcerans 
was conﬁ  rmed by PCR on the basis 
of the IS2404 repeated insertion se-
quences of M. ulcerans as described 
by Stinear et al. (8). The positive re-
sults were conﬁ  rmed by quantitative 
real-time PCR, in the Laboratory of 
Bacteriology at Central Hospitalier 
universistaire, Angers, France, on 2 
speciﬁ  c sequences: IS2404 sequence 
and ketoreductase B domain of the 
mycolactone polyketide synthase gene 
from the plasmid pMUM001 (9).
According to WHO criteria, 2 
conﬁ  rmative test results should be ob-
tained of 4 laboratory tests (ZN stain-
ing, positive culture of M.ulcerans, 
speciﬁ   c gene ampliﬁ  cation,  pathog-
nomonic histopathologic features) to 
establish a deﬁ   nitive diagnosis (7). 
Concerning the 2 patients in this study, 
results of ZN staining and PCR were 
positive, thus conﬁ  rming the diagno-
sis of Buruli ulcer. Samples were in-
oculated on Löwenstein-Jensen (LJ) 
media and incubated at 30°C for 2 
months, but the culture did not grow 
the organism. This result could be ac-
counted for by the paucity of bacilli in 
the samples. In conclusion, our study 
conﬁ   rms that, although infrequently 
diagnosed, Buruli ulcer is an endemic 
disease in CAR.
Identiﬁ  cation and control of Bu-
ruli ulcer remain difﬁ   cult in CAR, 
where this disease is often not con-
sidered. Even with evocative clinical 
signs, conﬁ   rmation of diagnosis by 
biological analysis is still not easy. It 
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Figure. Patient 1: extensive ulcer of the right limb (A). Patient 2: ulcer of the left ankle before treatment (B) and 8 weeks after speciﬁ  c 
antimicrobial drug therapy (C). Scale bars = 12 cm (A), 5 cm (B), and 2 cm (C).LETTERS
is therefore of high importance that 
the public health authorities are fully 
informed and properly trained to iden-
tify this neglected disease in the early 
stages so patients can be cured before 
the onset of functional impairment and 
the appearance of extensive lesions. 
Further investigation to isolate strains 
present in CAR is also essential.
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